One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Computerized technologies informing cardiac catheterization and guiding coronary intervention
ReteshBajajMBBS, MRCPabRamyaParasaMBBS, MRCPcAnantharamanRamasamyMBChB, MRCPabNicoleMakariouMScabNicolasFoinPhDdFrancescoPratiMDefAlexandraLanskyMDgAnthonyMathurMD, PhDabAndreasBaumbachMD, PhDabChristos V.BourantasMD, PhDabh
doi : 10.1016/j.ahj.2021.05.017
Volume 240, October 2021, Pages 28-45
Rationale and design of the comparison of outcomes and access to care for heart failure (COACH) trial: A stepped wedge cluster randomized trial
Douglas S.LeeMD,PhDabcdSharon E.StrausMD,MScdePeter C.AustinPhDadShanasMohamedRN,BScNbMonicaTaljaardPhDfgAliceChongBScaJimingFangPhDaTreesaPrasadBScaMichael E.FarkouhMD,MScbdMichael J.SchullMD,MScadhSusannaMakMD,PhDdiHeather J.RossMD,MHScbcd
doi : 10.1016/j.ahj.2021.05.003
Volume 240, October 2021, Pages 1-10
Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial)
RajivAnanthakrishnaMBBS, MD, DMabcSau LLeePhDcJonathonFooteRNbBenedetta CSallustioPhDdeGiuliaBindaMDbcArduino AMangoniPhDfRichardWoodmanPhDgChristopherSemsarianMBBS,PhD, MPHhiJohn DHorowitzPhDjJoseph BSelvanayagamMBBS,DPhilabc
doi : 10.1016/j.ahj.2021.06.010
Volume 240, October 2021, Pages 101-113
Cardiac rehabilitation availability and characteristics in Latin America and the Caribbean: A Global Comparison
AudryChacin-SuarezMDaSherry L.GraceMDbClaudiaAnchique-SantosMDcMartaSuperviaMDadKaramTurk-AdawiMDeRaquel R.BrittoMDfDawn C.ScantleburyMDgFelipeAraya-RamirezMDhGracielaGonzalezMDiBriseidaBenaimMDjRosaliaFernandezMDkJacquelineHolMDlGerardBurdiatMDmRichardSalmonMDnHermesLomeliMDoTaslimaMamatazMDbJose R.Medina-InojosaMDaFranciscoLopez-JimenezMDa
doi : 10.1016/j.ahj.2021.05.010
Volume 240, October 2021, Pages 16-27
Renin–angiotensin–aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system
Alexander TSandhuMD, MSa1ShunKohsakaMDbShoutzuLinMScChristopher YWooMD, MSdMary K.GoldsteinMDcePaul AHeidenreichMD, MSac
doi : 10.1016/j.ahj.2021.06.004
Volume 240, October 2021, Pages 46-57
Infective endocarditis and solid organ transplantation: Only worse outcomes during initial transplantation hospitalization
Emily M.EichenbergerMDaMichaelDagherMDaMatthew R.SinclairMDbStacey A.MaskarinecMD, PhDaVance G.FowlerJr.MD, MHSaJerome J.FederspielMD, PhDcd
doi : 10.1016/j.ahj.2021.06.007
Volume 240, October 2021, Pages 63-72
Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials
GadCotterMDabBeth A.DavisonPhDabChristopherEdwardsBSaStefanieSengerPhDaJohn R.TeerlinkMDcFaiezZannadMDdOlav WendelboeNielsenMDeMarcoMetraMDfAlexandreMebazaaMDgOvidiuChioncelMDhBarry HGreenbergMDiAldo PMaggioniMDjGeorgErtlMDkNaokiSatoMDlAlainCohen-SolalMDm
doi : 10.1016/j.ahj.2021.06.001
Volume 240, October 2021, Pages 73-80
The challenge of sustainability: Long-term results from the Fifty-Fifty peer group-based intervention in cardiovascular risk factors
Juan MiguelFernández-AlviraPhDaRodrigoFernández-JiménezMD, PhDabMercedesde MiguelMScacGloriaSantos-BeneitPhDacdPatriciaBodegaMsCacChristopher AHillBAdVanesaCarralPhDcCarlaRodríguezMSccIsabelCarvajalMSccXavierOrritPhDcAmayade Cos-GandoyMsCacMarianDal ReBSceTeresaRobledoMDeValentínFusterMD, PhDacd
doi : 10.1016/j.ahj.2021.06.006
Volume 240, October 2021, Pages 81-88
Relation of renal function to mid-term prognosis of stable angina patients with high- or low-dose pitavastatin treatment: REAL-CAD substudy
MitsuruAbeMD,PhDaYukioOzakiMD,PhDbHiroshiTakahashiBSccMitsuruIshiiMD,PhDaNobutoyoMasunagaMDaTevfik F.IsmailPhD,FRCPdSatoshiIimuroMD,PhDeRetsuFujitaMSeHiroshiIwataMD,PhDfIchiroSakumaMD,PhDgYoshihisaNakagawaMD,PhDhKiyoshiHibiMD,PhDiTakafumiHiroMD,PhDjYoshihiroFukumotoMD,PhDkSeijiHokimotoMD,PhDlKatsumiMiyauchiMD,PhDfHisaoOgawaMD,PhDmHiroyukiDaidaMD,PhDfHiroakiShimokawaMD,PhDnYasushiSaitoMD,PhDoMasunoriMatsuzakiMD,PhDpMasaharuAkaoMD,PhDaTakeshiKimuraMD,PhDqRyozoNagaiMD,PhDr
doi : 10.1016/j.ahj.2021.06.009
Volume 240, October 2021, Pages 89-100
Mental health disorders and emergency resource use and outcomes in ventricular assist device supported patients
Jonathan JEdwardsa†Jonathan BEdelsonabc†HannahKatcoffdAntaraMondaldDebraLefkowitzeNosheenRezafThomas CHanfffHeatherGriffisdJeremy AMazurekfJoyceWaldfAnjali TOwensfCarol AWittlieb-WeberaDanielle SBursteinaPavanAtlurigMatthew JO'ConnoraLee RGoldbergbhPaymanZamanidPeter WGroeneveldbgJoseph WRossanoabKimberly YLinaEdo YBiratibhi
doi : 10.1016/j.ahj.2021.05.018
Volume 240, October 2021, Pages 11-15
There are limited data describing the prevalence of mental health disorders (MHDOs) in patients with ventricular assist devices (VADs), or associations between MHDOs and resource use or outcomes. We used the Nationwide Emergency Department Sample administrative database to analyze 44,041 ED encounters for VAD-supported adults from 2010 to 2017, to assess the relationship between MHDOs and outcomes in this population. MHDO diagnoses were present for 23% of encounters, and were associated with higher charges and rates of admission, but lower mortality.
Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry
Paul L.HessMD, MHS1Kensey L.GoschMS2Sandeep M.JaniMD, MPH3Paul D.VarosyMD1Steven M.BradleyMD, MPH4Thomas M.MaddoxMD, MSc5P.Michael HoMD, PhD1Salim S.ViraniMD, PhD6
doi : 10.1016/j.ahj.2021.04.017
Volume 240, October 2021, Pages 58-62
Recent data suggest direct oral anticoagulants are as safe and efficacious as warfarin among select patients with valvular heart disease and atrial fibrillation (AF). However, real-world treatment patterns of AF stroke prophylaxis in the setting of valvular AF are currently unknown. Accordingly, using the prospective, ambulatory National Cardiovascular Data Registry Practice Innovation and Clinical Excellence (PINNACLE) Registry, we sought to characterize overall use, temporal trends in use, and the extent of practice-level variation in the use of any direct oral anticoagulant and warfarin among patients with valvular AF from January 1, 2013, to March 31, 2019.
